Biomarkers of liver failure in mechanical jaundice as preclinical indicators reflecting the development of the pathological process
Open Access
- 12 August 2026
- journal article
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
Abstract
The issue of liver failure arising from mechanical jaundice is a pressing issue for intensive care. The main goals of treatment are to replace and maintain liver function, prevent or minimize the development of secondary complications from organs and systems. Traditionally, a range of different methods is used in the diagnosis of liver failure arising from mechanical jaundice, ranging from instrumental, biochemical, serological, immunological, to the most complex molecular biological studies. However, generally accepted indicators do not always reflect the depth of damage to the liver parenchyma and the severity of the pathological process, which requires a search for specific markers of liver damage as indicators of the severity of the patient's condition and predictors of the outcome of the disease. Potential candidates should have high topical diagnostics, specificity and sensitivity in the first hours of the disease. According to the literature, the following biomarkers of liver injury potentially meet these requirements: liver form of fatty acid binding protein, 5-nucleotidase, liver arginase, hyaluronic acid. However, we believe that the issue of their reliability for assessing the condition of patients and predicting the outcome of liver failure against the background of mechanical jaundice remains insufficiently studied, which necessitates further research.Keywords
This publication has 29 references indexed in Scilit:
- Biomarkers of liver diseasesMolecular Biology Reports, 2023
- Acute-on-chronic liver failure (ACLF) in 2022: have novel treatment paradigms already arrived?Expert Review of Gastroenterology & Hepatology, 2022
- Prognostic significance of preoperative hyaluronic acid level in patients with hepatocellular carcinomaHPB, 2022
- Review of arginase as a promising biocatalyst: characteristics, preparation, applications and future challengesCritical Reviews in Biotechnology, 2021
- The elegant complexity of mammalian ecto-5′-nucleotidase (CD73)Trends in Cell Biology, 2021
- Hepatic Encephalopathy: From Metabolic to NeurodegenerativeNeurochemical Research, 2021
- A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinomaInvestigational New Drugs, 2021
- Adipocyte Fatty Acid–Binding Protein as a Predictor of Outcome in Alcohol-induced Acute-On-Chronic Liver FailureJournal of Clinical and Experimental Hepatology, 2021
- Addition of hyaluronic acid to the FIB‐4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes StudyObesity Science & Practice, 2021
- Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinomaJournal of Cellular Physiology, 2018